Title : Tetrahydro-(2H)-1,3,5-thiadiazine-2-thione (THTT), A versatile carrier system for targeting cell cycle checkpoint pathways with potential anticancer activities
Abstract:
Cancer remains a global health threat despite advances in research and technology. According to International Agency for Research on Cancer, the cancer burden will increase by about 77% by 2050, further straining health systems, people and communities. Although cancer chemotherapy has progressed in major strides in recent years, there is still an unmet need for new anti-cancer agents with good potency, diminished toxicity and able to treat tumors that are resistant to currently known drugs. In recent years, cell cycle and checkpoint pathways regulation are offering new therapeutic approaches against cancer. Targeting the cell cycle holds promise but further optimization is necessary to fully exploit it as an anti-cancer strategy across diverse malignancies. Tetrahydro-(2H)-1,3,5-thiadiazine-2-thione (THTT) nucleus has been verified for its anticancer activities. It has been postulated that the anticancer activities of THTT is mainly based on their role as carrier system generating the active species in the biosystem. Furthermore, Preliminary biological evaluation revealed that THTT carrier system possess notable cell growth inhibitory activity by disrupting the cell cycle with enhanced selectivity against cancer cells, suggesting the potential for the development of new selective cell cycle inhibitors. Encouraged by the above and in continuation of our synthetic work on THTT it seemed interesting to prompted to develop THTT as a new class of carriers to these active species of molecules.
Audience Take Away Notes:
- Development of new Drug Delivery System
- Potential of Structure based drug design for drug discovery and development
- How to improve the activities of the current clinically approved drugs
- Opening the windows for global scientific collaborations
- Improvement of the accuracy of drug design and providing new information to assist in solving drug design problems
